Brokerages Set Personalis, Inc. (NASDAQ:PSNL) PT at $11.67

Personalis, Inc. (NASDAQ:PSNL) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $11.6667.

A number of equities analysts have weighed in on PSNL shares. BTIG Research cut their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. TD Cowen reissued a “buy” rating on shares of Personalis in a research note on Wednesday. Morgan Stanley upped their price objective on Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st.

Insider Activity

In other news, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,558,668.88. The trade was a 29.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock valued at $5,599,929 over the last 90 days. 4.20% of the stock is currently owned by insiders.

Institutional Trading of Personalis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its position in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Personalis during the fourth quarter worth approximately $31,000. Legal & General Group Plc purchased a new stake in Personalis during the second quarter worth approximately $30,000. BNP Paribas Financial Markets increased its position in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Personalis in the fourth quarter worth $82,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Price Performance

NASDAQ PSNL opened at $15.58 on Tuesday. Personalis has a 12 month low of $3.84 and a 12 month high of $16.15. The company has a 50-day moving average of $10.75 and a 200-day moving average of $8.85. The company has a market cap of $1.63 billion, a P/E ratio of -15.27 and a beta of 2.24.

Personalis (NASDAQ:PSNL) last released its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.48 million. As a group, equities research analysts anticipate that Personalis will post -1.07 EPS for the current year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.